alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
John,
<This is why the terms that GTC gets from its past partners can be used to determine true market cap value.>
Of course that is a gross simplification and misrepresentation. Didn't you ever hear the phrase "past performance does nto guarantee future results". Each deal will differ depending on what product is being partnered. In addition, previous deals came prior to EMEA approval of rATIII. Following FDA approval of rATIII, the metric for deals will once again shift in GTCB's favor for futurer partnerships.
<Some of you are saying this is a 10 baggers opportunity when Gtcb was trading at around 1. Now...this got to be a 20 baggers one...>
Correct. You have mastered elementary mathematics.
I knew there was at least one educated man on this board. Now if we could only make some money on GTCB, we could all have the leisure time to become as educated as oldberkeley.
Ah, another wonderful day in GTCB land. If this kind of day happens a few more times I may start to get worried. :)
I bought some more GTCB today at $0.46, which is my second buy in about a week. I have now increased my shares by 25% in all. Come on Cox, roll a seven with the partnership.
That would send me to the bar, to celebrate!
Speaking of a flush, I just increased my shares of GTCB by 10%. I hope it this latest buy turns out to be like the card hand and not the action of a certain device in the bathroom :)
Thurly,
The size of the deal is one factor in the probability of getting it done. You can't compare a $40 billion dollar deal with one in the $50 million range, which is where GTCB would be. The former requires lots of loans and multiple parnters while the GTCB type deal could easily be done by the partnering company without any outside financing.
lew
<<At this point I would be overjoyed to get in bed with either.>>
Me too. I guess we will both be trolling this weekend for a little nookie!
MTB,
I am doing well. Hope you are the same. I also still have high hopes for GTCB but just feel resigned to the likelihood that more declines are coming. I just wish Cox would make some kind of gesture to conserving some cash, and he could even say that it is a contingency plan to cover the "remote" possibility that the deal will take longer than he expects. I hope you don't mind a little sarcasm there, but I couldn't resist. The thing is that GTCB could really turn around with even a moderately good deal.
Vinny
dufus,
You spell out one possible scenerio that is better that bankruptcy, but I would hardly call it the best case scenerio at this point.
okay, you are crazy :)
MTB,
Thanks for the much needed humor and the hopeful metaphor for GTCB. Just one question. Was the deputy who scared the goat off the bridge named Cox?
Vinny
There are many types of VPs. What was this person a VP in accounting?
Sounds like the person from Baxter is either an idiot or completely out of the loop if he or she hasn't heard about transgenically produced plasma proteins. So, what is this person's position and responsibilities. Is the person an accountant?
oldberkeley,
You know, a few minutes after the scene you depicted from the Maltese Falcon, Bogart takes the gun away from Petter Lorre and knocks him out. Can we expect that later scene from you upon Cox's partnership announcement for rATIII?
Vinny
Dew,
Thanks for transcript of the CC. I was pleased at what I read on a number of issues, especially that GTCB is trying to get a deal where the partner will fund and or conduct the clinical trials for rATIII in acquried deficiencies. Now, if the damn partnership will only materialize. Still, the delay and the "diversion" of the original partner could end being a plus for GTCB. Like in dating, sometimes interest goes way up when the partner feels there is competition for one's affection. Yes, I know I am a hopeless optimist.
Vinny
Dew,
Thanks for the chart of possible uses for rATIII in different acquired deficiences. When the partnership finally does materialize, I would like to see them fully fund trials in one or more of them. The point is we need to expand rATIII past only sepsis since I don't know if GTCB could survive if the sepsis news is bad.
Vinny
It would be too low an offer. I say we hold out for more!!
Cro,
I am thinking along your lines. I doubt there will be any solid announcement about the partnership and the financial picture will look worse than in the last CC.
I did buy some more ONXX today just ahead of their earnings report.
Lew,
Could you explain in more detail?
When GTCB announce their partnership, one of the things I would like to see is that the partner will quickly initiate rATIII trials in aquired indications other than sepsis. GTCB keeps mentioning the myriad uses of rATIII. It would really back up their comments if say a trial begins for coronary heart bypass for example. This would validate GTCB's and keep rATIII and GTCB's eggs from being all in the sepsis basket. I would also like the parner to be responsibile for all the expenses. Is that too much to ask??
oldberkely,
Thanks for making me spit out what I was drinking. She kind of looks like my
ex-wife. The scene you depicted looks like when I kept saying, "honey, how long is this headache going to last, after all I have needs".
Johnbits,
I understand you but you are making my point for me. A perception of current economic conditions, and speculation as to how consumers will respond as well as what people are guessing what might happen in the future is causing AAPL's price to fluctuate. It is not something intrinsic to AAPL's current financial status.
My AAPL example is very valid. The market priced APPL as a greater than $200/share stock, then a $120 stock now a greater than $170 stock. The latter two with essentially zero new AAPL specific information.
Yes I have checked my emotions and I feel disgusted and a bit anxious that GTCB is so low. But that doesn't change my view that it is greatly undervalued. GTCB management does share a good deal of the blame because of their partnership in a few weeks comment way back in Dec and the fact they didn't build up more of a cash cushion. But that doesn't change my view that GTCB is worth a hell of a lot more than what the market says it is right now. The cash crunch is killing the stock price, and once that is resolved to buy more time, then I will feel a lot better. Of course in the near term, the terms of the deal could either lower or raise the stock price. This uncertainty has killed GTCB stock as the low volume shows as everyone is waiting to see exactly what this purported deal is.
The stock market doesn't value a company based on its balance sheet, in the short or long term. Emotions, both fear and greed are major drivers that distort the price. It can be fear or greed that is specific to the stock or to the overall market. Just look at APPL, a company that is as far from GTCB as is possible. It was over $200, then dropped to the $120 just after the past earnings report and is now over $170. What, did the company's intrinsic value get really bad and then really improve, all over the course of a few months?
Quantum,
<My only caution is that although the data points they have are good (safety, equivalence etc.,) they are very few in number. I know this is in a very small patient population and larger trials were not commercially feasible.>
I can't rule out an advisory panel. But you have to keep in mind that GTCB worked with the FDA to design the phase III trial and it was decided then how many patients were need for GTCB to generate sufficient data to merit approval. The phase III trial utilized the requisite number of patients and passed with flying colors. This makes the idea that there were too few patients a bit of a red herring. I do agree that an advisory panal still cannot be ruled out given that rATIII will be the first transgenic protein approved. Howver, I must agree with Dew, I would be far more confident of approval if no panel was convened.
Dew,
Congratulations to you as well. Thanks for the info about MNTA and for all your efforts regarding GTCB.
Vinny
My tequila puking, I mean, drinking colleague was swearing that he only got sick because he ate red tortilla chips before dinner, and they were bad. We still laugh about that today because when we see each other at a meeting, one will say, "stay away from the red chips"
The funny thing is right after he left here, he flew to visit one of his (and my) buddy from graduate school. They went camping and both got so drunk they partially burned down the tent they were sleeping in. When he got back home he didn't drinking a drop of booze for 6 months after his twin ordeals. I think he got into aging research to try and reverse some of the damage he did to himself over that 3 week period.
Vinny
Dew,
What does MNTA have?
MTB,
Funny but I know quite well some of the people who discovered the whole Sir2 connection to aging. One of the current big shots in aging came to my lab for 2 weeks when he was a grad student to learn a technique I had developed. The second to the last night he was here we went out and drank a boat load of tequila. The guy ended up falling out of the taxi when we got home and then vomited at the top of the strairs of my then apartment. I discretely remind him of this every couple of years.
There is a lot of really cool aging work going on now. I was initially pretty skeptical but now think there is a pretty good chance of significantly extending lifespan, or at least making us feel a lot younger and healthier until we die. I don't think resveritol will be the big drug though or even the only drug.
I do agree that we will be laughing about how dumb the market as to keep GTCB so low for so long. PGNX had a nother big rise today on apostive opinion from the EMEA on hteir drug MNTX. The FDA will make its decisn in a few days so there is a good shot at anopther even bigger boost. I increased my shares of PGNX by 40% at $5.26 and $7 a few weeks ago so am looking ot unload about 10% if the FDA does approve. If so, I will likely be adding more GTCB and also some ONXX with my PGNX profits
Dop you have any favorites other than GTCB?
MTB,
Congratulations. I didn't buy SIRT because I thought it was too early stage and speculative. GTCB is far more advanced and closer to a breakthrough on several fronts. I expect a bigger rise than the SIRT one awaits GTCB soon. I just need GTCB to remain lower a bit longer until PGNX get a positive news from the FDA and the EMEA very soon. It has already been rising in anticipation of such news and the shorts are panicing.
<I hate to say this...but I think we will never see > $1 again...the patents that GTCB holds do not interest big pharmas whatsoever.>
It would be more accurate to say you should be embarassed to say what you did. Do you think GTCB's patents have no value? Big pharma will try to do what they can to keep the status quo. What you fail to grasp is that GTCB doesn't need all of big pharma, they just need to win over one of them or some mid-sized pharma with cash and the need for a pipeline. When some positive rATIII data for an acquired deficiency is generated, there will be cracks in the wall of obfuscation and misrepresentation and big pharma will jump on the bandwagon for fear of being left behind.
<<One of the problems GTC faces is that transgenic production in mammals (for use in a mammal) has several risks that the other hosts don't carry.>>
Right, and the other systems carry risks that GTCB doesn't.
oldberkeley,
You are the king!! I salute you. You fit the picture with the comment perfectly. Dew's absolute indifference to the woman's (the market or Dew's wife) pleas shows a defiance of the petty worries of the uniformed. Dew's confidence in GTCB oozes forth and stands in stark contrast to the fearful visage.
Sorry Dew, you should know better than the challenge oldberkeley.
johnsmallbits,
There is an old saying "Better to keep one's mouth shut and be thought a fool, than to open ones mouth and remove all doubt."
Thank you for removing all doubt. It is clear that you don't have a clue and or are engaging in out right lies for some reason. There is no comparison AT ALL between INGN and GTCB.
I think you need to up your meds since you are contradicting yourself by saying GTCB has been reliable and honest about their pipeline, then following with the claim that Cox and management pumped GTCB as being better than gold. On the contrary, he has been quite conservative and never pumped GTCB as being good as gold nor even stated how high he thinks the stock price woud go.
Why don't you provide some links to public comments that Cox made? You know the ones where he pumped GTXB for being better than gold. If you can't find one he made, then find one for anyone currently in GTCB managment.
<This investment has proven to be a great place to park cash.>
Right now I feel like I got a parking ticket!
Oldeberkely,
Just what I needed. A big laugh in the morning. Thanks so much.
I didn't know shareholders had class. Aren't they all greedy little bast*rds?
As Tom Petty sings "The waiting is the hardest part"!